Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Gothenburg, March 10, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company's commercially available iTANK platform, congratulates its Chief Scientific Officer, Professor Magnus Essand, who has been named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden). The award is given in recognition of his groundbreaking and world-unique research in immunotherapy, where, through advanced clinical studies, he is developing the next generation of cancer treatments.
Magnus Essand is a professor at Uppsala University and co-founder of Elicera Therapeutics. His translational research combines gene therapy, cell therapy, and immunotherapy-with a particular focus on CAR-T treatments. His research group in Uppsala was the first in Europe to conduct CAR-T treatment in 2014. In the ongoing Phase I/IIa clinical trial CARMA, using the company's iTANK-armed CAR T-cell therapy ELC-301, six out of eight evaluated patients have so far achieved complete metabolic response (CMR)-meaning disease-free status-one month after treatment. Of the six patients with confirmed CMR at month one, four had sustained CMR at their most recent recorded follow-up. The best responses have so far been confirmed to last up to at least 12 months.
The Swedish Cancer Society (Cancerfonden) motivates the award as follows:
"Professor Magnus Essand is named Cancer Researcher of the Year with the following motivation: For world-unique research in immunotherapy against cancer. With sharp molecular engineering, he has created innovative cell therapies that have made the full journey from the laboratory to patients, with results that save lives."
Malin Sund, professor and chair of Cancerfonden's research committee, says:
"Magnus Essand is a pioneer in immunotherapy in Europe. His research has already led to results that have changed the lives of patients and holds the potential to cure significantly more people in the future. This is research that we believe will make a very large and real difference for cancer patients."
Magnus Essand comments:
"Immunotherapy has seen a major breakthrough over the past ten years, but we are still only at the beginning. Our goal is to develop treatments that are more precise and can cure more patients. This is the most fun and interesting thing I know-it's both a job and a hobby."
Elicera Therapeutics CEO Jamal El-Mosleh says:
"We are incredibly proud of Magnus Essand's achievement and that his groundbreaking work is now being recognized with this prestigious award. His research lies at the heart of Elicera's mission to develop the next generation of immunotherapies using our iTANK platform. This prize underscores the high quality and potential in our pipeline and strengthens our position in cell and gene therapy against cancer."
The award will be presented on March 10, 2026, in connection with Cancerfonden's 75th anniversary.